NA Syndromic Multiplex Diagnostic Market - Industry Trends and Forecast to 2029

Description

List of Tables

The North America syndromic multiplex diagnostic market is projected to register a CAGR of 9.0% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2020, and the forecast period is 2022 to 2029.

Market Segmentation:

North America Syndromic Multiplex Diagnostic Market, By Product and Services (Reagents & Consumables, Instruments, Software & Accessories and Services), Infection type (Viral, Bacterial, Parasites and Fungal), Disease (Respiratory Infections, Gastroenteritis, Sexually Transmitted Infections, Sepsis, Meningitis and Others), Panels Type (Respiratory Panel, GI-Enteric Panel, SexuallyTransmitted Disease Panel, Blood-Sepsis Panel, Meningitis panel and Others), End User (Clinical Laboratories, Hospitals, Pharmaceutical & Biotechnology Companies, Research Institutes and Others), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2029.

Some of the major factors contributing to the growth of North America syndromic multiplex diagnostic market are:

Increase in prevalence of infectious diseases

Growing technological advancement

Increasing regulatory approval

Market Players:

The major companies which are dealing in the North America syndromic multiplex diagnostic are listed below:

BioFire Diagnostics (A Subsidiary of bioMerieux SA)

Seegene Inc.

Luminex Corporation. A DiaSorin Company

F. Hoffmann-La Roche Ltd

Bio-Rad Laboratories, Inc.

Cepheid (A subsidiary of Danaher)

QIAGEN

Abbott

Hologic, Inc.

Thermo Fisher Scientific Inc.

Siemens Healthcare GmbH

Akonni Biosystems, Inc.

Biocartis

QuantuMDx Group Ltd.

Applied BioCode, Inc.

Prominex Inc.

Nanomix, Inc

Curetis (A subsidiary of OpGen, Inc.)

1 INTRODUCTION 27

1.1 OBJECTIVES OF THE STUDY 27
1.2 MARKET DEFINITION 27
1.3 OVERVIEW OF NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET 27
1.4 LIMITATIONS 29
1.5 MARKETS COVERED 29

2 MARKET SEGMENTATION 32

2.1 MARKETS COVERED 32
2.2 GEOGRAPHICAL SCOPE 33
2.3 YEARS CONSIDERED FOR THE STUDY 34
2.4 CURRENCY AND PRICING 34
2.5 DBMR TRIPOD DATA VALIDATION MODEL 35
2.6 MULTIVARIATE MODELLING 38
2.7 PRODUCT AND SERVICES LIFELINE CURVE 38
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 39
2.9 DBMR MARKET POSITION GRID 40
2.10 MARKET END USER COVERAGE GRID 41
2.11 VENDOR SHARE ANALYSIS 42
2.12 SECONDARY SOURCES 43
2.13 ASSUMPTIONS 43

3 EXECUTIVE SUMMARY 44

4 PREMIUM INSIGHTS 46

4.1 PESTEL ANALYSIS 48
4.2 PORTER'S FIVE FORCES 49
4.3 MARKET SHARE PER PANEL, FOR TOP 3 PLAYERS (2021) 50

5 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: REGULATIONS 51

6 MARKET OVERVIEW 54

6.1 DRIVERS 56
- 6.1.1 RISING PREVALENCE OF INFECTIOUS DISEASES 56
- 6.1.2 RISING ADOPTION OF MOLECULAR DIAGNOSTICS TECHNIQUES 57
- 6.1.3 INCREASING REGULATORY APPROVAL FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) TESTING 58
- 6.1.4 INCREASING DEMAND FOR FAST AND ACCURATE DIAGNOSTIC RESULTS 58
6.2 RESTRAINTS 59
- 6.2.1 HIGH COST OF DIAGNOSTIC PRODUCTS 59
- 6.2.2 EXPLICIT LIMITATION OF SYNDROMIC MULTIPLEX DIAGNOSTIC 59
6.3 OPPORTUNITIES 60
- 6.3.1 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS 60
- 6.3.2 RISING DIAGNOSTIC HEALTHCARE EXPENDITURE 60
- 6.3.3 INTRODUCTION OF TECHNOLOGICAL ADVANCED PRODUCTS 62
6.4 CHALLENGES 63
- 6.4.1 PRODUCT RECALLS 63
- 6.4.2 LACK OF SKILLED PROFESSIONALS AND BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS 63

7 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT & SERVICES 64

7.1 OVERVIEW 65
7.2 REAGENTS & CONSUMABLES 68
7.3 INSTRUMENTS, SOFTWARE & ACCESSORIES 68
7.4 SERVICES 69

8 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE 71

8.1 OVERVIEW 72
8.2 VIRAL 75
- 8.2.1 CORONAVIRUS 76
- 8.2.2 INFLUENZA VIRUS 76
- 8.2.3 ADENOVIRUS 76
- 8.2.4 RHINOVIRUS 76
- 8.2.5 ROTAVIRUS 76
- 8.2.6 OTHERS 76
8.3 BACTERIAL 77
- 8.3.1 PNEUMONIAE 78
- 8.3.2 BORDETELLA PERTUSSIS 78
- 8.3.3 STAPHYLOCOCCUS 78
- 8.3.4 OTHERS 78
8.4 PARASITES 78
8.5 FUNGAL 79

9 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE 81

9.1 OVERVIEW 82
9.2 RESPIRATORY INFECTIONS 85
9.3 GASTROENTERITIS 86
9.4 SEXUALLY TRANSMITTED INFECTIONS 86
9.5 SEPSIS 87
9.6 MENINGITIS 88
9.7 OTHERS 89

10 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE 91

10.1 OVERVIEW 92
10.2 RESPIRATORY PANEL 95
10.3 GI-ENTERIC PANEL 95
10.4 SEXUALLY TRANSMITTED DISEASE PANEL 96
10.5 BLOOD-SEPSIS PANEL 97
10.6 MENINGITIS PANEL 98
10.7 OTHERS 99

11 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER 100

11.1 OVERVIEW 101
11.2 HOSPITALS 104
11.3 CLINICAL LABORATORIES 104
11.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 105
11.5 RESEARCH INSTITUTES 106
11.6 OTHERS 107

12 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION 108

12.1 NORTH AMERICA 109
- 12.1.1 U.S. 116
- 12.1.2 CANADA 119
- 12.1.3 MEXICO 122

13 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY LANDSCAPE 125

13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 125

14 SWOT ANALYSIS 126

15 COMPANY PROFILE 127

15.1 BIOFIRE DIAGNOSTICS (A SUBSIDIARY OF BIOMERIEUX SA) 127
- 15.1.1 COMPANY SNAPSHOT 127
- 15.1.2 REVENUE ANALYSIS 127
- 15.1.3 COMPANY SHARE ANALYSIS 128
- 15.1.4 PRODUCT PORTFOLIO 128
- 15.1.5 RECENT DEVELOPMENTS 129
15.2 F. HOFFMANN-LA ROCHE LTD 130
- 15.2.1 COMPANY SNAPSHOT 130
- 15.2.2 REVENUE ANALYSIS 130
- 15.2.3 COMPANY SHARE ANALYSIS 131
- 15.2.4 PRODUCT PORTFOLIO 131
- 15.2.5 RECENT DEVELOPMENT 132
15.3 LUMINEX CORPORATION. A DIASORIN COMPANY 133
- 15.3.1 COMPANY SNAPSHOT 133
- 15.3.2 RECENT FINANCIALS 133
- 15.3.3 COMPANY SHARE ANALYSIS 134
- 15.3.4 PRODUCT PORTFOLIO 134
- 15.3.5 RECENT DEVELOPMENT 135
15.4 CEPHEID (A SUBSIDIARY OF DANAHER) 136
- 15.4.1 COMPANY SNAPSHOT 136
- 15.4.2 RECENT FINANCIALS 136
- 15.4.3 COMPANY SHARE ANALYSIS 137
- 15.4.4 PRODUCT PORTFOLIO 137
- 15.4.5 RECENT DEVELOPMENTS 138
15.5 QIAGEN 139
- 15.5.1 COMPANY SNAPSHOT 139
- 15.5.2 RECENT FINANCIALS 139
- 15.5.3 COMPANY SHARE ANALYSIS 140
- 15.5.4 PRODUCT PORTFOLIO 140
- 15.5.5 RECENT DEVELOPMENT 140
15.6 ABBOTT 141
- 15.6.1 COMPANY SNAPSHOT 141
- 15.6.2 REVENUE ANALYSIS 141
- 15.6.3 PRODUCT PORTFOLIO 142
- 15.6.4 RECENT DEVELOPMENT 142
15.7 AKONNI BIOSYSTEMS, INC. 143
- 15.7.1 COMPANY SNAPSHOT 143
- 15.7.2 PRODUCT PORTFOLIO 143
- 15.7.3 RECENT DEVELOPMENT 143
15.8 APPLIED BIOCODE, INC. 144
- 15.8.1 COMPANY SNAPSHOT 144
- 15.8.2 PRODUCT PORTFOLIO 144
- 15.8.3 RECENT DEVELOPMENTS 145
15.9 BD 146
- 15.9.1 COMPANY SNAPSHOT 146
- 15.9.2 REVENUE ANALYSIS 146
- 15.9.3 PRODUCT PORTFOLIO 147
- 15.9.4 RECENT DEVELOPMENTS 147
15.10 BIOCARTIS 148
- 15.10.1 COMPANY SNAPSHOT 148
- 15.10.2 REVENUE ANALYSIS 148
- 15.10.3 PRODUCT PORTFOLIO 149
- 15.10.4 RECENT DEVELOPMENT 149
15.11 BIO-RAD LABORATORIES, INC. 150
- 15.11.1 COMPANY SNAPSHOT 150
- 15.11.2 REVENUE ANALYSIS 150
- 15.11.3 PRODUCT PORTFOLIO 151
- 15.11.4 RECENT DEVELOPMENT 151
15.12 BOSCH HEALTHCARE SOLUTIONS GMBH (A SUBSIDIARY OF ROBERT BOSCH GMBH) 152
- 15.12.1 COMPANY SNAPSHOT 152
- 15.12.2 REVENUE ANALYSIS 152
- 15.12.3 PRODUCT PORTFOLIO 153
- 15.12.4 RECENT DEVELOPMENT 153
15.13 CURETIS (A SUBSIDIARY OF OPGEN, INC.) 154
- 15.13.1 COMPANY SNAPSHOT 154
- 15.13.2 RECENT FINANCIALS 154
- 15.13.3 PRODUCT PORTFOLIO 155
- 15.13.4 RECENT DEVELOPMENTS 155
15.14 HOLOGIC, INC. 156
- 15.14.1 COMPANY SNAPSHOT 156
- 15.14.2 RECENT FINANCIALS 156
- 15.14.3 PRODUCT PORTFOLIO 157
- 15.14.4 RECENT DEVELOPMENT 157
15.15 MIRXES PTE LTD. 158
- 15.15.1 COMPANY SNAPSHOT 158
- 15.15.2 PRODUCT PORTFOLIO 158
- 15.15.3 RECENT DEVELOPMENT 158
15.16 NANOMIX, INC. 159
- 15.16.1 COMPANY SNAPSHOT 159
- 15.16.2 PRODUCT PORTFOLIO 159
- 15.16.3 RECENT DEVELOPMENT 159
15.17 PROMINEX INC. 160
- 15.17.1 COMPANY SNAPSHOT 160
- 15.17.2 PRODUCT PORTFOLIO 160
- 15.17.3 RECENT DEVELOPMENT 160
15.18 QUANTUMDX GROUP LTD. 161
- 15.18.1 COMPANY SNAPSHOT 161
- 15.18.2 PRODUCT PORTFOLIO 161
- 15.18.3 RECENT DEVELOPMENTS 161
15.19 SEEGENE INC. 162
- 15.19.1 COMPANY SNAPSHOT 162
- 15.19.2 REVENUE ANALYSIS 162
- 15.19.3 PRODUCT PORTFOLIO 163
- 15.19.4 RECENT DEVELOPMENTS 166
15.20 SIEMENS HEALTHCARE GMBH 167
- 15.20.1 COMPANY SNAPSHOT 167
- 15.20.2 RECENT FINANCIALS 167
- 15.20.3 PRODUCT PORTFOLIO 168
- 15.20.4 RECENT DEVELOPMENT 168
15.21 THERMOFISHER SCIENTIFIC INC. 169
- 15.21.1 COMPANY SNAPSHOT 169
- 15.21.2 RECENT FINANCIALS 169
- 15.21.3 PRODUCT PORTFOLIO 170
- 15.21.4 RECENT DEVELOPMENT 170

16 QUESTIONNAIRE 171

17 RELATED REPORTS 174

LIST OF TABLES

TABLE 1 COST OF THE PRODUCT 49
TABLE 2 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION) 57
TABLE 3 NORTH AMERICA REAGENTS & CONSUMABLES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 58
TABLE 4 NORTH AMERICA INSTRUMENTS, SOFTWARE & ACCESSORIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 59
TABLE 5 NORTH AMERICA SERVICES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 60
TABLE 6 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 64
TABLE 7 NORTH AMERICA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 65
TABLE 8 NORTH AMERICA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 66
TABLE 9 NORTH AMERICA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 67
TABLE 10 NORTH AMERICA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 68
TABLE 11 NORTH AMERICA PARASITES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 69
TABLE 12 NORTH AMERICA FUNGAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 70
TABLE 13 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 74
TABLE 14 NORTH AMERICA RESPIRATORY INFECTIONS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 75
TABLE 15 NORTH AMERICA GASTROENTERITIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 76
TABLE 16 NORTH AMERICA SEXUALLY TRANSMITTED INFECTIONS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 77
TABLE 17 NORTH AMERICA SEPSIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 78
TABLE 18 NORTH AMERICA MENINGITIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 79
TABLE 19 NORTH AMERICA OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 80
TABLE 20 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 84
TABLE 21 NORTH AMERICA RESPIRATORY PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 85
TABLE 22 NORTH AMERICA GI-ENTERIC PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 86
TABLE 23 NORTH AMERICA SEXUALLY TRANSMITTED DISEASE PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 87
TABLE 24 NORTH AMERICA BLOOD-SEPSIS PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 88
TABLE 25 NORTH AMERICA MENINGITIS PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 89
TABLE 26 NORTH AMERICA OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 89
TABLE 27 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 93
TABLE 28 NORTH AMERICA HOSPITALS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 94
TABLE 29 NORTH AMERICA CLINICAL LABORATORIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 95
TABLE 30 NORTH AMERICA PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 96
TABLE 31 NORTH AMERICA RESEARCH INSTITUTES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 96
TABLE 32 NORTH AMERICA OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 97
TABLE 33 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 103
TABLE 34 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 103
TABLE 35 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 103
TABLE 36 NORTH AMERICA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 104
TABLE 37 NORTH AMERICA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 104
TABLE 38 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 104
TABLE 39 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 105
TABLE 40 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 105
TABLE 41 U.S. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 106
TABLE 42 U.S. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 106
TABLE 43 U.S. VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 106
TABLE 44 U.S. BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 107
TABLE 45 U.S. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 107
TABLE 46 U.S. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 107
TABLE 47 U.S. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 108
TABLE 48 CANADA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 109
TABLE 49 CANADA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 109
TABLE 50 CANADA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 109
TABLE 51 CANADA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 110
TABLE 52 CANADA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 110
TABLE 53 CANADA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 110
TABLE 54 CANADA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 111
TABLE 55 MEXICO SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 112
TABLE 56 MEXICO SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 112
TABLE 57 MEXICO VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 112
TABLE 58 MEXICO BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 113
TABLE 59 MEXICO SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 113
TABLE 60 MEXICO SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 113
TABLE 61 MEXICO SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 114

LIST OF FIGURES

FIGURE 1 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SEGMENTATION 21
FIGURE 2 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DATA TRIANGULATION 24
FIGURE 3 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DROC ANALYSIS 25
FIGURE 4 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS 26
FIGURE 5 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS 26
FIGURE 6 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS 28
FIGURE 7 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID 29
FIGURE 8 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: END USER COVERAGE GRID 30
FIGURE 9 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS 31
FIGURE 10 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SEGMENTATION 34
FIGURE 11 INCREASING PREVALENCE AND INCIDENCE OF INFECTIOUS DISEASES IS EXPECTED TO DRIVE THE NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET IN THE FORECAST PERIOD 35
FIGURE 12 REAGENTS & CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET IN 2022 & 2029 35
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD 36
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET 44
FIGURE 15 TOTAL CASES OF COVID-19 IN NORTH AMERICA 45
FIGURE 16 TOTAL CASES OF COVID-19 IN EUROPE 46
FIGURE 17 NATIONAL HEALTH EXPENDITURE VS MEDICAL DEVICE EXPENDITURE, U.S., 2019 50
FIGURE 18 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, 2021 54
FIGURE 19 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, 2022-2029 (USD MILLION) 55
FIGURE 20 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, CAGR (2022-2029) 55
FIGURE 21 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, LIFELINE CURVE 56
FIGURE 22 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, 2021 61
FIGURE 23 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, 2022-2029 (USD MILLION) 62
FIGURE 24 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, CAGR (2022-2029) 62
FIGURE 25 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, LIFELINE CURVE 63
FIGURE 26 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, 2021 71
FIGURE 27 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, 2022-2029 (USD MILLION) 72
FIGURE 28 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, CAGR (2022-2029) 72
FIGURE 29 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, LIFELINE CURVE 73
FIGURE 30 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, 2021 81
FIGURE 31 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, 2022-2029 (USD MILLION) 82
FIGURE 32 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, CAGR (2022-2029) 82
FIGURE 33 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, LIFELINE CURVE 83
FIGURE 34 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, 2021 90
FIGURE 35 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, 2022-2029 (USD MILLION) 91
FIGURE 36 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, CAGR (2022-2029) 91
FIGURE 37 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE 92
FIGURE 38 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SNAPSHOT (2021) 99
FIGURE 39 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2021) 100
FIGURE 40 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2029) 100
FIGURE 41 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2021 & 2029) 101
FIGURE 42 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT AND SERVICES (2022-2029) 101
FIGURE 43 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY SHARE 2021 (%) 114